Press Room

DDL 2022

Start
Wednesday, December 07, 2022 - 09:00
End
Friday, December 09, 2022 - 09:00
Location: Scotland, UK
Booth Number: 244

 

Visit Hovione’s booth at DDL next December 7-9 in Edinburgh and connect with one of our Inhalation Experts.

Schedule a meeting today
DDL – Drug Delivery to the Lungs
Stand #244

 

Hovione is a specialist integrated CDMO offering services for drug substance, drug product intermediate and drug product for oral and inhaled solutions. When looking for a fully Integrated Solution Provider for Inhalation, Hovione offers Customized high-performance APIs, Particle Engineering and Formulation along with a full range of highly specialized, innovative Inhalation Devices

Let’s discuss your project from feasibility to commercial.
 

 

In Edinburgh don’t miss Hovione’s poster presentations:

#39 - Evaluation of Performance of Dry Powder Inhaler Formulations by Laser Diffraction

Luís Sousa, Senior Analytical Scientist, R&D Analytical Development, Analytical Methodologies and Method Development

#48 - Capsule Filling of Spray Dried Powders for Inhalation using a Drum Filling technology: From Lab to Pilot Scale

Rui Churro, Scientist, R&D Inhalation & Advanced Drug Delivery, Process Development

#51 - Enhanced engineered formulations in dry powder inhalers for high dose lung delivery

Susana Saldanha, Manager, R&D Inhalation & Advanced Drug Delivery, Formulation Development

#53 - Simulation lung dissolution – fast-tracking DPI development

Hovione scientists with Inhalation Sciences

 

Schedule a meeting today

 

Find more about DDL2022

 

 

Also in the Press Room

See All

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025